TY - JOUR T1 - Prevention of adrenal crisis: cortisol responses to major stress compared to stress dose hydrocortisone delivery in adrenal insufficiency JF - medRxiv DO - 10.1101/2020.02.08.20021246 SP - 2020.02.08.20021246 AU - Alessandro Prete AU - Angela E Taylor AU - Irina Bancos AU - David J Smith AU - Mark A Foster AU - Sibylle Kohler AU - Violet Fazal-Sanderson AU - John Komninos AU - Donna M O’Neil AU - Dimitra A Vassiliadi AU - Christopher J Mowatt AU - Radu Mihai AU - Joanne L Fallowfield AU - Djillali Annane AU - Janet M Lord AU - Brian G Keevil AU - John AH Wass AU - Niki Karavitaki AU - Wiebke Arlt Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/02/11/2020.02.08.20021246.abstract N2 - Context Patients with adrenal insufficiency require increased hydrocortisone cover during major stress to avoid life-threatening adrenal crisis. However, current treatment recommendations are not evidence-based.Objective To identify the most appropriate mode of hydrocortisone delivery in patients with adrenal insufficiency exposed to major stress.Design and Participants Cross-sectional study: 122 unstressed healthy subjects and 288 subjects exposed to different stressors (major trauma [N=83], sepsis [N=100], and combat stress [N=105]). Longitudinal study: 22 patients with preserved adrenal function undergoing elective surgery. Pharmacokinetic study: 10 patients with primary adrenal insufficiency undergoing administration of 200mg hydrocortisone over 24 hours in four different delivery modes (continuous intravenous infusion; six-hourly oral, intramuscular or intravenous bolus administration).Main Outcome Measure We measured total serum cortisol and cortisone, free serum cortisol and urinary glucocorticoid metabolite excretion by mass spectrometry. Linear pharmacokinetic modelling was used to determine the most appropriate mode and dose of hydrocortisone administration in patients with adrenal insufficiency exposed to major stress.Results Serum cortisol was increased in all stress conditions, with the highest values observed in surgery and sepsis. Continuous intravenous hydrocortisone was the only administration mode persistently achieving median cortisol concentrations in the range observed during major stress. Linear pharmacokinetic modelling identified continuous intravenous infusion of 200mg hydrocortisone over 24 hours, preceded by an initial bolus of 50-100mg hydrocortisone, as best suited for maintaining cortisol concentrations in the required range.Conclusions Continuous intravenous hydrocortisone infusion should be favored over intermittent bolus administration in the prevention and treatment of adrenal crisis during major stress.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Medical Research Council UK (program grant G0900567, to WA), the Oxfordshire Health Services Research Committee (NK), and the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham (grant reference number BRC-1215-2009, to WA and JML). AP is a Diabetes UK Sir George Alberti Research Training Fellow (grant reference number 18/0005782). IB is the recipient of a Robert and Elizabeth Strickland Career Development Award, the James A Ruppe Career Development Award in Endocrinology, and the Mayo Clinic Catalyst Award for Advancing in Academics. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care UK. The funders of the study had no role in the: design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; decision to submit the manuscript for publication. Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request. ER -